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Abstract
Angiogenesis is a hallmark of tumor development and metastasis and now a validated target for cancer treatment.
We previously reported that a novel dimer peptide (apoEdp) derived from the receptor binding region of human
apolipoprotein E (apoE) inhibits virus-induced angiogenesis. However, its role in tumor anti-angiogenesis is unknown. This
study demonstrates that apoEdp has anti-angiogenic property in vivo through reduction of tumor growth in a mouse model
and ocular angiogenesis in a rabbit eye model. Our in vitro studies show that apoEdp inhibits human umbilical vein
endothelial cell proliferation, migration, invasion and capillary tube formation. We document that apoEdp inhibits vascular
endothelial growth factor-induced Flk-1 activation as well as downstream signaling pathways that involve c-Src, Akt, eNOS,
FAK, and ERK1/2. These in vitro data suggest potential sites of the apoE dipeptide inhibition that could occur in vivo. This is
the first evidence that a synthetic dimer peptide mimicking human apoE has anti-angiogenesis functions and could be an
anti-tumor drug candidate.
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Introduction
Angiogenesis is defined as the formation of new blood vessels
from pre-existing vasculature. Angiogenesis is relevant not only to
cancer but also to non-neoplastic diseases including macular
degeneration, psoriasis, endometriosis, and arthritis [1,2]. The
growth and metastasis of tumors are critically dependent on
angiogenesis [3,4]. Thus, the inhibition of angiogenesis has
become an important therapeutic strategy for cancer [5]. Although
the existing anti-angiogenesis therapies have been reported to have
less toxicity than conventional chemo or radiotherapy, they are
often associated with clinical side effects, and limited tumor
regression [6]. Therefore, there has been an increased focus
toward development of novel angiogenesis inhibitors and novel
approaches to maximize the anti-angiogenic therapies [7].
Human apolipoprotein E (apoE) is one of the most frequently
studied proteins known to be involved in lipid metabolism and
cardiovascular disorders [8]. Experimental studies on apoE are
focused on its receptor binding region, which is located between
residues 130–150 and is critical for its biological activity. This
receptor binding region of apoE is known to be responsible for
binding apoE to the low-density lipoprotein receptor [9]. Within
this receptor binding region, residues 142–147, also known as
heparin-binding domain, mediate the attachment of apoE to
cellular heparan sulfate proteoglycan (HSPG) [10,11]. HSPG is an
integral component of cell surface extracellular matrix that is
ubiquitous in nature and plays important roles in the regulation of
several aspects of cancer biology, including angiogenesis, tumor
progression, and metastasis [12,13]. Several growth factors
including vascular endothelial growth factor (VEGF) and their
receptors (VEGFR) bind to HSPG molecules to facilitate cellular
and biochemical responses [14]. Thus, molecules having the
ability to block these interactions and inhibiting processes crucial
to tumor progression are considered as a new class of cancer
therapeutics [15,16]. A tandem-repeat dimer peptide called
apoEdp, derived from the apoE residues 141–149, has been
reported by others to exhibit anti-infective activity in vitro [17,18]
and also in our in vivo studies [19,20]. During our experimental
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models, we recognized that apoEdp inhibited virus-induced
corneal angiogenesis. Thus, we have investigated whether apoEdp
has the ability to inhibit angiogenesis in two in vivo non-infectious
models of ocular and tumor angiogenesis. The role of apoEdp as
an anti-angiogenic agent is unknown.
VEGF and its endothelial receptors VEGFR has been the subject
of great interest in angiogenesis research [21]. Tumor cells secrete
VEGF [22,23]. Endothelial VEGF receptors, particularly VEGF
receptor 2(KDR/Flk-1) has been reported to initiate critical
signaling pathways through interaction with VEGF, leading to
tumor angiogenesis [24]. Targeting the VEGF signaling pathways is
a well-known validated approach for anti-tumor therapy [24].
Inhibition of VEGF has been shown to be effective in cancer [25]
and ocular angiogenesis [26]. Although VEGF-triggered angiogen-
esis is not fully understood, groups of signaling molecules such as
cSrc [27,28], FAK [28], Akt [29], ERK1/2 [30] and eNOS [31]
have been reported to be involved in VEGF signaling cascades. It
has been reported that VEGF treatment of ECs promotes cell
survival, proliferation and migration, mainly through the activation
of Flk-1 receptor [32,33]. The activated Flk-1 subsequently binds to
c-Src and phosphorylates it [34]. c-Src phosphorylation and c-Src-
mediated FAK phosphorylation are essential for the VEGF
signaling pathways and in angiogenesis [35]. Reports suggest that
c-Src becomes activated following binding to phosphorylated Flk-1
receptor upon VEGF stimulation, with subsequent activation of
downstream molecules, including ERK1/2 phosphorylation [36].
VEGF-stimulated EC migration has been reported to result from
increased NO production via eNOS phosphorylation [37]. Akt
phosphorylation has been reported to be necessary for eNOS
activation, endothelial cell (EC) migration and angiogenesis [38]. In
this study, we investigated the anti-tumorigenic ability of apoEdp in
vitro and in vivo and examine the underlying cellular and molecular
mechanisms. Our in vitro results suggest that apoEdp inhibited
VEGF-induced human umbilical vein endothelial cell (HUVEC)
survival, migration, invasion, and capillary tube formation in vitro.
The in vivo rabbit eye model assay showed that apoEdp suppressed
VEGF-induced angiogenesis in a corneal micro-pocket assay. In the
mouse xenograft human breast cancer tumor model, apoEdp
significantly suppressed the growth of tumor without any observable
toxicity to mice.We also examined the signaling pathwaysrelatedto
angiogenesis. The apoEdp selectively blocked the activation of
VEGF receptor Flk-1 and the downstream signaling pathways of c-
Src, Akt, eNOS, FAK, and ERK1/2 activation. This is the first
evidence that a peptide derived from human apoE is a potential
anti-angiogenesis and anti-tumor therapeutic agent.
Results
ApoEdp affects the viability of endothelial cells but not
breast cancer cells (MDA-MB-231)
To confirm that apoEdp affects cell survival, cell viability was
determined using the cell titer 96HAQuous One solution cell
proliferation kit. ApoEdp treatment of HUVECs induced a dose-
dependent inhibition of cell viability (Fig. 1A). The 50% cytotoxicity
(CC50) determined in this assay was about 103 mM. To determine
whether apoEdp suppresses tumor growth by directly affecting tumor
cells, we performed a cell viability assay using human breast cancer
MDA-MB-231 cell line invitro and cell titer 96HAQuous One solution
cell proliferation kit. As shown in Fig. 1B, the 50% cytotoxic dose of
apoEdp against breast cancer cells was .300 mM, suggesting that
apoEdp has no significant direct effect on tumor cell proliferation.
ApoEdp inhibits endothelial cell migration/wound
healing
An important angiogenic phenotype of ECs induced by VEGF
is cell migration. The major aspects of VEGF action on ECs are its
ability to act as a chemoattractant and to stimulate the angiogenic
morphogenesis. We therefore examined the ability of apoEdp to
inhibit VEGF-induced HUVEC migration, since such migration is
relevant to angiogenesis and hence to tumor growth and
metastasis. Cell migration was examined after simulation of an
artificial wound by perturbation of a cell monolayer using a 1-mL
pipette tip. While using the wound healing assay to measure
changes in cell migration (Fig. 2A–B), we found that the inhibitory
effect of apoEdp on HUVEC migration is dose dependent at the
range of 6–100 mM; the 50% inhibitory concentration (IC50) for
this assay is approximately 21.5 mM. (Fig. 2C).
Figure 1. ApoEdp affects HUVEC survival but not MDA-MB-231. A. HUVEC: ApoEdp has a significant effect on VEGF-induced HUVEC
viability. Cells were treated with apoEdp at the indicated concentrations and incubated with constant 50 ng/mL VEGF for 48 hr. All values were
normalized to cell control of no VEGF and no apoEdp. Cell viability values (mean 6 SEM) are expressed as % of the value of the VEGF control. B.
MDA-MB-231: ApoEdp has no effect on MDA-MB-231viability. ApoEdp has no significant effect on MDA-MB-231 survival. Cells were treated with
apoEdp at the indicated concentrations and incubated at 37uC for 2 days. Cell viability values (mean 6 SEM) are expressed as % of the value of the
control (untreated cells). The asterisks indicate significant differences compared with VEGF stimulation. ** p,0. 01; and *** p,0.001.
doi:10.1371/journal.pone.0015905.g001
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The cellular mechanisms of angiogenesis involve motility and
alignment of ECs to form a capillary tube-like network on matrigel
[31]. Thus, we assessed whether or not apoEdp impaired EC
differentiation in the tube formation assay as described in the
Materials and Methods. The numbers of tubular structures
(Fig. 3A) were quantitatively analyzed. As shown in Fig. 3B,
apoEdp significantly inhibited the ability of HUVEC capillary
tube formation compared to VEGF control (VEGF only, no
peptide) in a concentration-dependent manner from the range of
6–50 mM; the IC50 for this assay was 9 mM. ‘‘Percentage (%) of
inhibition’’ in Fig. 3C is the mean number (6 SEM) of tubules
expressed as a proportion of that in the VEGF control group.
** p,0.01 and *** p,0.001.
ApoEdp inhibits endothelial cell invasion
The complex process of new blood vessel formation involves
migration and invasion of ECs. The inhibition of EC motility through
migration and invasion could thus be expected to affect the angiogenic
process. To evaluate the ability of apoEdp in blocking VEGF-induced
HUVEC migration and invasion, we used a Boyden chamber
transwell assay (Materials and Methods). We quantified the invasion
of HUVECs across the transwell. Cells which invaded across the
membranewere stained withhematoxylinand eosinstainand counted
(Fig. 4A–B). Compared to VEGF-induced control, apoEdp peptide
significantly inhibited VEGF-induced cell migration and invasion at a
dose range of 6–100 mM; the IC50 f o rt h i sa s s a yw a sa b o u t3 1 . 5mM
(Fig. 4C). All values were normalized to cell numbers of transwells
exposed to EBM containing 1% FBS without apoEdp and VEGF.
Figure 2. ApoEdp inhibits wound-healing migration in vitro. Monolayers of HUVECs were scraped and incubated in medium containing
50 ng/mL VEGF in the presence or absence of various concentrations of apoEdp. VEGF stimulated the migration of HUVECs in the scraped area.
Representative photomicrographs of cells treated with (A) VEGF alone or with (B) VEGF and apoEdp together are shown. Solid lines indicate the initial
scraping. (C) ApoEdp significantly inhibited the migration of HUVEC to the wounded area. The bar diagram is the quantitative measurement of cell
migration inside the scraped area. The data shown are representative of three independent experiments. ** p,0. 01; and *** p,0.001.
doi:10.1371/journal.pone.0015905.g002
Figure 3. ApoEdp inhibited capillary tubule formation (in vitro angiogenesis). About 4610
4 (per well) HUVECs in medium containing
50 ng/mL of VEGF were plated in 24-well plates previously coated with growth factor-reduced matrigel, and incubated for 12–16 hr at 37uC in the
absence or presence of apoEdp. Tubular structures were quantitated by manual counting under low power fields. Representative photomicrographs
of tubule formation in the (A) VEGF control and (B) apoEdp-treated wells are shown. (C) ‘‘Percentage (%) of inhibition’’ is the mean number (6 SEM) of
tubules expressed as a proportion of that in the VEGF control group. ** p,0.01 and *** p,0.001.
doi:10.1371/journal.pone.0015905.g003
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micropocket assay
To study the in vivo anti-angiogenic effect of apoEdp, we
assessed its inhibitory effect on VEGF-induced corneal micro-
pocket assay in rabbit eye model. The slow release micropellet
(500 mm6500 mm) of 0.4 g of Compritol 888 ATO (Gattefosse)
combined with 0.1 g of Squalane oil (Sigma) and 20 mg/mL L-a-
phosphatidylcholine containing saline or 160 ng of VEGF were
surgically implanted in the corneal micropocket created in the
avascular area of rabbit cornea (Fig. 5A–B). Topical application of
eye drops containing 1% apoEdp significantly inhibited VEGF-
induced angiogenesis compared to saline treated eyes (Fig. 5C).
Corneal micro-pocket application of mock-pellets containing
saline did not induce angiogenesis throughout the examination
period.
ApoEdp suppresses tumor growth in Nude (nu/nu) mice
xenograft model
In order to assess the in vivo effect of apoEdp on tumor growth,
we established subcutaneous human breast cancer MDA-MB-231
tumor xenografts in nude mice. Once tumor size became
,100 mm
3 in approximately 10 days, mice were randomly
divided into two groups, and treated with PBS or apoEdp at
40 mg/kg/day for three consecutive days. Representative photo-
graphs of apoEdp- or PBS-treated mouse xenografts are shown in
Fig. 6A–B. ApoEdp treatment significantly inhibited tumor growth
compared to PBS- treated controls (Fig. 6C). There was no sign of
observable toxicity and no significant body weight differences
between the two groups of mice (data not shown) were detected
during drug treatment.
ApoEdp inhibits VEGF-induced signaling pathways
Our results suggest that apoEdp significantly inhibited VEGF-
induced phosphorylation of Flk1 (Fig. 7-A), c-Src (Fig. 7-B), Akt
(Fig. 7-C), eNOS (Fig. 7-D), FAK (Fig. 7-E), and Erk1/2 (Fig. 7-F)
in a concentration-dependent manner.
Discussion
Cellular processes of tumor angiogenesis and metastasis involve
multiple steps including EC proliferation, migration, and differ-
entiation through tube formation, invasion and neo-angiogenesis
[1–4]. Peptides or compounds that inhibit any of the multistep
processes will lead to the disruption of angiogenesis and can serve
as potential candidates for therapeutic intervention against
angiogenesis [2].
Human apoE is a protein constituent of different plasma
lipoproteins and serves as a high-affinity ligand for several
receptors. By interacting with its receptors, apoE mediates the
clearance of different lipoproteins from the circulation [39].
Absence or structural mutations of apoE cause significant
disorders in lipid metabolism, cardiovascular disease, and
Alzheimer’s disease [8]. Specific peptide sequences derived from
the receptor-binding region of human apoE have been previously
reported by us [19,20] and others [17,18,40,41] to have anti-
infective and anti-inflammatory properties. No reports are
available about the effect of a peptide derived from human apoE
against tumor angiogenesis.
Apolipoprotein E shares a series of features with another
polymorphic apolipoprotein, apolipoprotein A [apoA] [42,43].
ApoA consists of tandemly repeated kringle domains that closely
resemble plasminogen kringle 4 (KIV) [44]. The apoA kringle
domains have been reported to inhibit angiogenesis in vitro [45]
and suppress tumor growth in vivo [46,47]. ApoA binds to the same
receptors as apoE [48,49]. Because of the similarities between
apoE and apoA in receptor binding, we hypothesized that the
apoE receptor domain is also associated with angiogenesis and
tumor growth.
ApoEdp sequence is derived from a region (ApoE142–149)o f
apoE known to bind cell surface heparan sulfate proteoglycan
(HSPG) of extracellular matrix (ECM) to exert its biological
functions [50,51]. HSPG-based antiangiogenic therapies have
been previously reported to be a method of choice in cases where
tumor angiogenesis depends on cell-surface HSPG [52,53]. The
Figure 4. ApoEdp inhibits endothelial cell invasion. About 4610
4 HUVECs were placed into each insert of Boyden chamber (0.8-mm pore size)
(BD Biosciences) of 24-well transwell plate. The bottom chambers were filled with 600 mL medium supplemented with 50 ng/mL VEGF. The top
chamber was seeded with approximately 4610
4 HUVEC cells/well in 100 mL containing different concentrations of apoEdp and incubated at 37uC for
16 hs. HUVEC cells were then fixed and stained with H&E and counted under the microscope. Representative photographs of (A) VEGF-treated and (B)
apoEdp-treated membranes are shown. The results show that the (C) HUVECs migrating across the transwell membrane are significantly suppressed
by the peptide apoEdp in a dose-dependent manner. **p,0.01 and ***p,0.001.
doi:10.1371/journal.pone.0015905.g004
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160 ng of VEGF were corneally implanted in New Zealand white rabbits (1.5–2.5 kg). The pellets were positioned about 2.0 mm from the corneal
limbus. Treatment began one day post-implantation (PI) and continued for five consecutive days. The right eye of all 5 rabbits was treated using 1%
peptide apoEdp, and left eye of the same rabbit received saline drops as mock treatment. Each eye drop (50 mL) was applied topically 5 times per day
every 2 hr starting at 8 AM and ending at 4 PM. Data and photos were obtained on days 3 through 10 after pellet implantation. (A)The area of
neovascular response, vessel length, and clock hours of new blood vessel of rabbits in each group were calculated according to the formula Area
(mm
2) =C/1263.1416 [r
22(r2L)
2] where C = the number of clock hours at the limbus involved in the neovascular response, L = length of the
longest neovascular pedicle from the limbus onto anterior cornea, and r = radius of the cornea. (B). ApoEdp significan.tly inhibited VEGF-induced
angiogenesis in rabbit corneal micro pocket assay. **p,0.01 and ***p,0.001.
doi:10.1371/journal.pone.0015905.g005
Figure 6. ApoEdp inhibits tumor growth in vivo. MDA-MB-231 breast cancer cells were used for anti-tumor studies. A suspension of 3610
6 cells
in 0.1 mL of PBS was injected in the right dorsal flank. Tumors were monitored weekly in two diameters with digital calipers. Tumor volumes were
determined using A6B
260.52 (where A is the longest and B is the shortest diameter). Tumors were allowed to grow to ,100 mm
3 and mice were
randomized. Single intralesional administration daily of PBS or 40 mg/kg/day of apoEdp for 3 consecutive days was performed and then stopped.
Representative photographs of mouse xenograft treated with (A) apoEdp or PBS are shown. (B) ApoEdp treatment significantly inhibited tumor
growth throughout the examination period. *p,0.05, and ***p,0.001.
doi:10.1371/journal.pone.0015905.g006
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mimetics have been reported to function by blocking these
interactions and inhibiting processes crucial to tumor progression
and, therefore, present a promising approach for new cancer
therapeutics [52,53]. One recent report [14] suggests that a
HSPG-binding peptide derived from VEGF inhibits tumor growth
by blocking angiogenesis in murine model. No reports are
available on whether a HSPG-binding peptide derived from the
receptor-binding region of human apoE E can inhibit tumor
growth by blocking angiogenesis.
Because tumor growth is dependent on tumor angiogenesis, and
angiogenesis inhibition is a novel therapeutic modality toward
controlling solid tumors, we demonstrate that apoEdp peptide
significantly inhibits tumor growth in nude mice with MDA-MB-
231 tumor cells. However, unlike HUVEC, the peptide has no
significant effect on the growth of MDA-MB-231 cells in vitro even
at a high concentration (300 mM). At the same time, apoEdp
peptide inhibited HUVEC cell migration and tube formation at
low concentrations in a wound-healing/migration assay, Boyden
chamber migration assay, and tube formation assays. The in vivo
effects of apoEdp on suppression of tumor growth suggest that
apoEdp is anti-tumorigenic by directly arresting EC growth and
indirectly starving tumor cell proliferation.
One possible mechanism of the anti-angiogenic property of
apoEdp could be related to our previous findings of the ability of
apoEdp is to interfere with herpes virus-induced angiogenesis via
inhibition of VEGF [19]. VEGF receptor-2 (Flk-1) is the primary
receptor in the VEGF signaling pathway that regulates angiogen-
esis [54]. In the present study, we report that apoEdp inhibits
VEGF-mediated receptor (VEGFR2/Flk-1) activation and down-
stream signaling (c-Src, FAK, Akt, eNOS, Erk1/2) pathways of
angiogenesis pertinent to tumor development and progression.
In conclusion, we showed for the first time that an 18-amino
acid dimer peptide (apoEdp) from human apolipoprotein E has
potential multi-targeted anti-angiogenic properties (Fig. 8). We
highlighted the roles of the apoEdp peptide in the inhibition of
tumor growth. In vitro, apoEdp inhibits EC survival, proliferation,
migration, and capillary tube formation. Angiogenesis inhibition
by apoEdp is regulated by selectively blocking VEGF-induced Flk-
1 receptor activation and downstream signaling pathway of c-Src-
Akt-eNOS, FAK, and Erk1/2. Our findings in the present study
could shed more light on the pharmacological activity of apoEdp
Figure 7. Inhibition by apoEdp of VEGF-induced Flk-1. HUVECs were pre-treated with apoEdp at the indicated concentrations for 1 hr; VEGF
(10 ng/mL) added and incubated at 37uC for 10 min, to measure the phosphorylation of Flk-1(7-A), c-Src(7-B), Akt(7-C), eNOS(7-D), FAK(7-E), and Erk1/
2(7-F). Equal loading of total proteins was also measured as described in Materials and Methods. Values were normalized by arbitrarily setting the
densitometry of control cell signals 1.0 (mean 6 SEM, n=5). The asterisks indicate significant differences compared with VEGF stimulation (*p,0.05,
**p,0.01 and ***p,0.001).
doi:10.1371/journal.pone.0015905.g007
Figure 8. A working model to explain anti-angiogenic activity
of apoEdp driven by VEGF. ApoEdp peptide suppresses tumor
growth through inhibition of VEGF-induced EC proliferation, migration,
invasion, and capillary tube formation.
doi:10.1371/journal.pone.0015905.g008
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suppression of tumor growth and metastasis.
Materials and Methods
Ethics Statement
The Xavier University of Louisiana Institutional Animal Care
and Use Committee approved this study (protocol 02-182009-1B),
as did the Louisiana State University Health Sciences Center in
New Orleans IACUC (protocol 2652). All studies were performed
in accordance with the Institute of Laboratory Animal Research
(NIH, Bethesda, MD) Guide for the Care and Use of Laboratory
Animals.
Cells and peptides
HUVEC cells were obtained from Lonza (Walkersville, MD)
and were maintained in EBM-2 (Lonza) supplemented with 10%
fetal bovine serum (FBS) and growth factors (bullet kit, Lonza).
HUVEC cells were used between passages 2–6. Human breast
cancer cell MDA-MB-231 was obtained from the American Type
Tissue Collection and cultured in Dulbecco’s Modified Eagle’s
medium supplemented with 10% fetal bovine serum, 0.1 mg/mL
streptomycin, and 25 U/mL penicillin. The apoE mimetic peptide
(apoEdp) was synthesized (Genemed, Arlington, TX) with a purity
of greater than 95%. The 18 amino acid (Ac-LRKLRKRLLL-
RKLRKRLL-amide) tandem-repeat dimer peptide (apoEdp) was
derived from the human apolipoprotein E receptor-binding region
between residues 141 and 149, as described previously [1,2,4].
Cell survival assays
VEGF-stimulated endothelial cell survival assay. The
effect of apoEdp on ED survival was evaluated. Passages 2 to 5
HUVECs were grown to sub-confluency in EBM2 medium
(Lonza) containing 10% FBS, EC growth supplement (bullet kit,
Lonza). The cells were seeded in 96-well plates at 10,000 per well
in EBM2 medium containing growth supplements (bullet kit;
Lonza) and 10% FBS. The next day, cells were starved for 18 hrs
in EBM2 + 1% FBS without any growth supplement and then
incubated with apoEdp in various concentrations. One hour later,
50 ng/mL of VEGF was introduced into the assay. Two days
later, cell numbers were determined using the CellTiter96
AQueous One solution cell proliferation kit (Promega, Madison,
WI).
Breast cancer cell survival assay. Cell survival studies were
carried out using the CellTiter96 AQueous One solution cell
survival assay. Briefly, cells were plated at about 5,000 MDA-MB-
231 cells/well in a 96-well plate and allowed to adhere to the plate
with different concentrations of peptides (6–300 mM). The cells
were incubated for 48 hr and then the AQueous One solution was
added to the samples and measured at 490 nm.
Wound-healing/migration assay. To determine the effect
of apoEdp on EC migration induced by VEGF, wound-healing
assays were performed using HUVEC cells. Cells were allowed to
grow to confluency on 6-well plates and washed twice with PBS.
Monolayer cells were wounded by scratching with 1-mL pipette
tip and washed 3 times with PBS and incubated for 8 h in EBM-2
without any growth supplements except 1% FBS. Following 8 hr
incubation, cells were supplemented with 1% FBS and 50 ng/mL
of VEGF, either in the presence or absence of the apoEdp (6–
100 mM). Control HUVEC cultures were incubated in EBM-2
plus 1% FBS in the absence of VEGF. Migration of the cells into
the wounded area was photographed with an Olympus U-RLF-T
microscope and counted. All values were normalized to control
without VEGF and apoEdp containing wells.
HUVEC matrigel tubule formation assay. Matrigel
(Sigma Aldrich, St Louis, MO) was thawed overnight on ice.
Each well of 24-well plates was coated at 4uC with 300 mL
matrigel and incubated at 37uC for 30 min. HUVECs were
harvested, and approximately 4610
4 cells/well were seeded in
1 mL medium with various concentrations of apoEdp peptide and
with/without 50 ng/mL of VEGF. After 12–16 hr, microtubule
formation was assessed with an inverted photomicroscope and the
images were photographed using Olympus U-RLF-T microscope.
Manual counting at low power fields was used to quantitate
tubular structures and percentage of inhibition was expressed
using VEGF control wells as 100%.
HUVEC cell migration/invasion assay. Boyden chamber
migration/invasion assays were performed. 24-well transwell (BD
Biosciences, San Jose, CA) migration chambers having an 8-mm
pore size were used. The transwells were placed in the 48-well
plate. The bottom chambers were filled with 600 mL of medium
supplemented with/without 50 ng/mL VEGF. The top chamber
was seeded with approximately 4610
4 HUVEC cells/well in
100 mL containing different concentrations of apoEdp peptide.
Cells were allowed to migrate for 16 hr at 37uC. Following
incubation, cotton swabs were used to gently scrape the cells on
the top surface of the membrane. After scraping of top surface,
cells on the bottom side of the membrane were fixed with 10%
buffered formalin for 1 hr, washed 3–5 times with PBS, and then
stained with hematoxylin and eosin. The cells were then de-stained
in PBS, and the transwell membrane was left to air dry at room
temperature. Transwell invaded cells were counted using an
inverted microscope. Three independent areas per filter were
counted, and the mean 6 SEM number of migrated cells was
calculated.
Rabbit corneal micropocket assay. Corneal micropockets
were created with a modified von Graefe cataract knife in eyes of
each 2–3 lbs NZ white rabbit. A micropellet (500 mm6500 mm) of
0.4 g of Compritol 888 ATO (Gattefosse) combined with 0.1 g of
Squalane oil (Sigma) and 20 mg/mL L-a-phosphatidylcholine
containing saline or 160 ng of VEGF was implanted into each
corneal pocket, positioned about 2 mm from the corneal limbus.
The right eye was implanted with a VEGF-containing pellet and
the left eye of the same rabbit was implanted with a saline-
containing pellet. A group of 5 rabbits was treated with 1%
apoEdp and another group of 5 rabbits was treated with saline as
eye drops. Treatment started one day post-implantation (PI) and
continued for five consecutive days. Each eye drop (50 mL) was
applied topically 5 times per day every 2 hr starting at 8 AM and
ending at 4 PM. Data and photos obtained on days 3 thru 10 after
pellet implantation are provided. The area of neovascular
response, vessel length, and clock hours of new blood vessels of
the rabbits in each group were calculated according to the formula
[55].
Area (mm
2) =C/1263.1416 [r
22(r2L)
2] where, C = the
number of clock hours at the limbus involved in the neovascular
response, L = length of the longest neovascular pedicle from the
limbus onto anterior cornea, and r = radius of the cornea.
Xenograft tumor growth assay in nude mice. Female nu/
nu mice (8–12 weeks old, weighing ,20 g) were obtained from
Charles River Laboratories (Harlan, Indianapolis, IN). Mice were
weighed, coded, and divided into experimental groups at random
(n=5 to 6). About 3610
6 MDA-MB-231 cells in 100 mL medium
were injected subcutaneously into the right sides of the dorsal area.
Peptides were intralesionally injected at the dose of 40 mg/kg/
day. The dose level was selected based upon pilot experiment of
safety and efficacy of apoEdp in xenograft mice tumor model (data
not shown). Control groups were injected only with sterile PBS.
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the tumor volume using digital calipers every 7 days. Tumor
volume was calculated [14] using the relationship A6B
260.52,
where A is the longest diameter and B the shortest. Mice were
euthanized 2 weeks after treatment.
Western blot analysis of angiogenic signaling molecules
Confluent HUVECs were grown in EBM-2 supplemented with
1% FBS for 24 hr and the medium was replaced with fresh low
serum (1% FBS) media in the presence or absence of varying
concentrations of apoEdp (6–50 mM). After 1 hr, VEGF was
added to a concentration of 10 ng/mL and incubated for 10 min
so that the phosphorylated forms of angiogenic signaling molecules
could be detected. The cells were then lysed, quantified for protein
concentration, and separated on 4–20% pre-cast SDS–PAGE gels.
Western blots of control and treated lysates were performed with
antibodies against the phospho form of Flk-1, c-Src, FAK, ERK1/
2, Akt, and eNOS. To show that equal amounts of protein have
been loaded, antibodies against total Flk-1, c-Src, FAK, ERK1/2,
Akt, and eNOS were used. All primary and secondary antibodies
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Statistical analysis
Result values were expressed as means and SEM, and the
significance was established by Student’s t test. In all analyses, the
level of statistical significance was more than 95% confidence
level (p, 0.05). *, **, or *** means p,0.05, p,0.01 or p,0.001,
respectively.
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